Dianthus Therapeutics (NASDAQ:DNTH) Announces Quarterly Earnings Results

Dianthus Therapeutics (NASDAQ:DNTH) posted its earnings results on Wednesday. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.13, FiscalAI reports. The company had revenue of $1.21 million for the quarter, compared to the consensus estimate of $0.46 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.

Dianthus Therapeutics Trading Up 3.8%

Shares of NASDAQ:DNTH traded up $3.11 on Wednesday, reaching $85.81. The company had a trading volume of 1,679,417 shares, compared to its average volume of 948,135. The firm has a market capitalization of $4.70 billion, a PE ratio of -20.68 and a beta of 1.47. Dianthus Therapeutics has a 52-week low of $32.42 and a 52-week high of $117.88. The firm’s 50 day simple moving average is $91.11 and its 200-day simple moving average is $85.18.

Analysts Set New Price Targets

Several research firms have commented on DNTH. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Thursday, October 15th. Citigroup initiated coverage on Dianthus Therapeutics in a report on Friday, September 4th. They set a “buy” rating and a $156.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $158.00 target price on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. Raymond James Financial reissued a “strong-buy” rating and set a $131.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, August 5th. Finally, Wedbush raised their target price on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $128.54.

Insider Activity

In related news, SVP Adam Veness sold 16,167 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $110.38, for a total transaction of $1,784,513.46. Following the completion of the sale, the senior vice president directly owned 3,833 shares in the company, valued at $423,086.54. This represents a 80.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Simrat Randhawa sold 23,124 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $106.41, for a total value of $2,460,624.84. Following the sale, the executive vice president directly owned 4,000 shares in the company, valued at approximately $425,640. The trade was a 85.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 242,429 shares of company stock worth $26,118,913 over the last ninety days. 3.02% of the stock is currently owned by corporate insiders.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for autoimmune and inflammatory diseases. The company’s research centers on the complement system, an important part of the immune response that can contribute to tissue damage and disease when improperly activated.

Dianthus’ lead product candidate, DNTH103, is an investigational, fully human monoclonal antibody designed to selectively inhibit C1s, a key protein in the classical complement pathway.